References
- Masoli M, Fabian D, Holt S, Beasley R. Global burden of asthma. Developed for the global initiative for asthma: Medical Research Institute of New Zealand, Wellington, New Zealand and University of Southampton, Southampton, United Kingdom; 2003
- Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469–78
- Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004;23:723–9
- Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003;111:1212–8
- Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002;19:61–7
- Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322–6
- Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636–42
- Global strategy for asthma management and prevention – revised 2006. Global initiative for asthma, 2006. http://www. ginasthma.org/Guidelineitem.asp??l1=2&l2=1&intId=60.) [accessed December 20, 2006]
- Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:32–9
- Sullivan SD. Asthma in the United States: recent trends and current status. J Manag Care Pharm 2003;9(Suppl 5):3–7
- Stern L, Berman J, Lumry W, et al. Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data. Ann Allergy Asthma Immunol 2006;97:402–8
- Bateman ED, Boushey HA, Bousquet J, et al. Can guidelinedefined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836–44
- Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13
- Gerrits CM, Herings RM, Leufkens HG, Lammers JW. Asthma exacerbations during first therapy with long acting beta 2-agonists. Pharm World Sci 1999;21:116–9
- Van Ganse E, Laforest L, Pietri G, et al. Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J 2002;20:260–7
- Hoskins G, McCowan C, Neville RG, et al. Risk factors and costs associated with an asthma attack. Thorax 2000;55:19–24
- Spector S. Noncompliance with asthma therapy – are there solutions? J Asthma 2000;37:381–8
- Kaiser HB. Compliance and noncompliance in asthma. Allergy Asthma Proc 2007;28:514–6
- Sullivan SD, Rasouliyan L, Russo PA, et al. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007;62:126–33